227 related articles for article (PubMed ID: 18591219)
1. Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptors.
Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2008 Oct; 327(1):161-7. PubMed ID: 18591219
[TBL] [Abstract][Full Text] [Related]
2. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
[TBL] [Abstract][Full Text] [Related]
3. Cocaine alters vesicular dopamine sequestration and potassium-stimulated dopamine release: the role of D2 receptor activation.
Farnsworth SJ; Volz TJ; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2009 Mar; 328(3):807-12. PubMed ID: 19038779
[TBL] [Abstract][Full Text] [Related]
4. Methylphenidate-induced alterations in synaptic vesicle trafficking and activity.
Volz TJ; Farnsworth SJ; Hanson GR; Fleckenstein AE
Ann N Y Acad Sci; 2008 Oct; 1139():285-90. PubMed ID: 18991873
[TBL] [Abstract][Full Text] [Related]
5. Method development and validation of an in vitro model of the effects of methylphenidate on membrane-associated synaptic vesicles.
Volz TJ; Farnsworth SJ; Hanson GR; Fleckenstein AE
J Neurosci Methods; 2009 Feb; 177(1):177-82. PubMed ID: 18992277
[TBL] [Abstract][Full Text] [Related]
6. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Neurosci; 2002 Oct; 22(19):8705-10. PubMed ID: 12351745
[TBL] [Abstract][Full Text] [Related]
7. Bupropion increases striatal vesicular monoamine transport.
Rau KS; Birdsall E; Hanson JE; Johnson-Davis KL; Carroll FI; Wilkins DG; Gibb JW; Hanson GR; Fleckenstein AE
Neuropharmacology; 2005 Nov; 49(6):820-30. PubMed ID: 16005476
[TBL] [Abstract][Full Text] [Related]
8. Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.
Chu PW; Hadlock GC; Vieira-Brock P; Stout K; Hanson GR; Fleckenstein AE
J Neurochem; 2010 Oct; 115(2):325-32. PubMed ID: 20649837
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein.
Truong JG; Newman AH; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2004 Nov; 504(1-2):27-32. PubMed ID: 15507217
[TBL] [Abstract][Full Text] [Related]
10. Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors.
Brown JM; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2001 Sep; 298(3):1150-3. PubMed ID: 11504813
[TBL] [Abstract][Full Text] [Related]
11. Muscarinic receptor activation attenuates D2 dopamine receptor mediated inhibition of acetylcholine release in rat striatum: indications for a common signal transduction pathway.
Drukarch B; Schepens E; Stoof JC
Neuroscience; 1990; 37(1):1-9. PubMed ID: 1978737
[TBL] [Abstract][Full Text] [Related]
12. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits.
Sandoval V; Riddle EL; Hanson GR; Fleckenstein AE
J Pharmacol Exp Ther; 2003 Mar; 304(3):1181-7. PubMed ID: 12604695
[TBL] [Abstract][Full Text] [Related]
13. Cocaine modulates allosteric D
Beggiato S; Borelli AC; Borroto-Escuela D; Corbucci I; Tomasini MC; Marti M; Antonelli T; Tanganelli S; Fuxe K; Ferraro L
Cell Signal; 2017 Dec; 40():116-124. PubMed ID: 28923416
[TBL] [Abstract][Full Text] [Related]
14. Methylphenidate alters basal ganglia neurotensin systems through dopaminergic mechanisms: a comparison with cocaine treatment.
Alburges ME; Hoonakker AJ; Horner KA; Fleckenstein AE; Hanson GR
J Neurochem; 2011 May; 117(3):470-8. PubMed ID: 21323925
[TBL] [Abstract][Full Text] [Related]
15. Methylphenidate modifies overflow and presynaptic compartmentalization of dopamine via an α-synuclein-dependent mechanism.
Chadchankar H; Ihalainen J; Tanila H; Yavich L
J Pharmacol Exp Ther; 2012 May; 341(2):484-92. PubMed ID: 22344407
[TBL] [Abstract][Full Text] [Related]
16. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity.
Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE
Synapse; 2009 Feb; 63(2):147-51. PubMed ID: 19021208
[TBL] [Abstract][Full Text] [Related]
17. Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors.
Ugarte YV; Rau KS; Riddle EL; Hanson GR; Fleckenstein AE
Eur J Pharmacol; 2003 Jul; 472(3):165-71. PubMed ID: 12871750
[TBL] [Abstract][Full Text] [Related]
18. D1 and D2 specific dopamine antagonist modulate the caudate nucleus neuronal responses to chronic methylphenidate exposure.
Venkataraman S; Claussen C; Dafny N
J Neural Transm (Vienna); 2017 Feb; 124(2):159-170. PubMed ID: 27853928
[TBL] [Abstract][Full Text] [Related]
19. Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores.
Schmitz Y; Lee CJ; Schmauss C; Gonon F; Sulzer D
J Neurosci; 2001 Aug; 21(16):5916-24. PubMed ID: 11487614
[TBL] [Abstract][Full Text] [Related]
20. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.
Gobert A; Rivet JM; Audinot V; Cistarelli L; Spedding M; Vian J; Peglion JL; Millan MJ
J Pharmacol Exp Ther; 1995 Nov; 275(2):899-913. PubMed ID: 7473181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
